RecruitingPhase 1NCT05544240

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

Phase 1 Trial of SYNC-T - Immunotherapy Regimen Given After Controlled Cellular Lysis for Patients With Advanced/Metastatic Solid Tumors

Sponsor

Williams Cancer Foundation

Enrollment

20 participants

Start Date

Feb 1, 2023

Study Type

INTERVENTIONAL

Conditions

Metastatic Breast Cancer Cancer Metastatic Cancer Metastatic Lung Cancer Solid Tumor

Summary

SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a new type of immunotherapy called SYNC-T for people with advanced or metastatic solid tumors — cancers that have spread and have not responded to standard treatments. The goal is to understand if this therapy is safe and to find the right dose. **You may be eligible if...** - You are 18 years or older - You have an advanced or metastatic solid tumor confirmed by biopsy - Your cancer has progressed after standard therapies or no standard treatment is available - Your heart has been cleared for treatment - You have stopped using blood thinners at least 5 days before each treatment **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have untreated or active brain metastases - You have serious heart, liver, or kidney problems - You are currently using blood thinners that cannot be stopped Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.